We are live on ! Find out more
HRTX icon

Heron Therapeutics

91 hedge funds and large institutions have $881M invested in Heron Therapeutics in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 39 increasing their positions, 23 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more call options, than puts

Call options by funds: $12.4M | Put options by funds: $7.25M

70% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 23

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

4% more capital invested

Capital invested by funds: $848M → $881M (+$33.2M)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

1% less funds holding

Funds holding: 9291 (-1)

Holders
91
Holders Change
-1
Holders Change %
-1.09%
% of All Funds
2.43%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.16%
New
12
Increased
39
Reduced
23
Closed
13
Calls
$12.4M
Puts
$7.25M
Net Calls
+$5.17M
Net Calls Change
-$2.19M
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
101
Cadence Capital Management
Massachusetts
-$275K -15,227 Closed
Jacobs Levy Equity Management
102
Jacobs Levy Equity Management
New Jersey
-$191K -10,560 Closed
Teacher Retirement System of Texas
103
Teacher Retirement System of Texas
Texas
-$75K -4,138 Closed
IA
104
IFP Advisors
Florida
-$204 -11 -92%

HRTX Hedge Fund Activity: Q3 2016 in Review

91 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2016, worth a combined $881M — up 3.9% from $848M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of HRTX and 12 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 39 added.

The largest buyer was Kingdon Capital Management, adding an estimated $33.1M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $8.89M sold.

  • 91 institutional investors held Heron Therapeutics (HRTX) as of Q3 2016, down from 92 in Q2 2016.
  • Funds reported $881M of Heron Therapeutics stock for Q3 2016, up 3.9% quarter-over-quarter.
  • 12 funds opened new Heron Therapeutics positions in Q3 2016 and 13 closed out, a net change of -1 holder.
  • The largest Heron Therapeutics buyer in Q3 2016 was Kingdon Capital Management, an estimated $33.1M added.
  • The largest Heron Therapeutics seller in Q3 2016 was Tekla Capital Management, an estimated $8.89M sold.

Based on aggregated 13F filings for Q3 2016.